Denali Therapeutics Inc.

Denali Therapeutics Inc. Misses on Revenue, Stock Down 4.27%

Denali Therapeutics reported a wider-than-expected loss per share, which was a positive surprise compared to expectations. However, the lack of revenue information and no guidance update contributed to a negative stock reaction, with shares falling 4.27%. Investors may be concerned about the company's future performance without clearer direction.